Merck's CETP inhibitor meets in CV outcomes study

Merck & Co. Inc. (NYSE:MRK) reported data from the Phase III REVEAL trial in patients at risk for cardiac events showing that once-daily 100 mg oral anacetrapib (MK-0859) met the primary endpoint of reducing major coronary events defined as a composite of coronary death, myocardial infarction (MI) or coronary revascularization vs. placebo. The double-blind, U.K. trial enrolled about 30,000 patients at high risk of cardiovascular events who were already receiving effective LDL-lowering treatment with atorvastatin for a median duration of ≥4 years. Data will be presented at the European Society of Cardiology meeting in Barcelona in August...